The effect of using microplegia on perioperative morbidity and mortality in elderly patients undergoing cardiac surgery.
Old age is a significant risk factor for perioperative morbidity and mortality following cardiac surgery and optimal myocardial protection strategy should be sought in this group of patients. We, therefore, reviewed the data on 295 consecutive patients older than 75 years who underwent any cardiac surgical procedure. Microplegia was used in 144 patients compared to 151 patients who had the standard 4:1 blood cardioplegia. Logistic regression analysis was used for propensity matching to balance the differences between the two groups. The microplegia group included more females and sicker patients as indicated by higher Parsonnet scores. There were differences in the pump time, aortic cross-clamp time, procedure type and surgeons between the two groups. These differences were balanced using the propensity matching. In-hospital mortality, acute renal injury and confusion were higher in the microplegia group (17%, 34%, 35%, respectively) compared to the standard 4:1 cardioplegia group (9%, 23%, 24%, respectively) (P=0.04, 0.04, 0.04, respectively). These differences were not statistically significant after propensity matching. These results demonstrate that the use of microplegia is safe in patients older than 75 years who are undergoing cardiac surgery and results in similar in-hospital morbidity and mortality to the standard 4:1 blood cardioplegia.
Division of Cardiothoracic Surgery, Department of Surgery, McGill University Health Centre, McGill University, Montreal, Canada. dr_turki@yahoo.com
Turki B
TB
Albacker
Rakesh
R
Chaturvedi
Adil H
AH
Al Kindi
Hamad
H
Al-Habib
Talal
T
Al-Atassi
Benoit
B
de Varennes
Kevin
K
Lachapelle
D000208:Acute Disease; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001803:Blood Transfusion; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000401:mortality*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003221:Confusion / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006324:Heart Arrest, Induced / Q000379:methods*; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control; D006400:Hematocrit; D017052:Hospital Mortality; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control; D016015:Logistic Models; D008297:Male; D018579:Patient Selection; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
D015415:Biomarkers; D002316:Cardiotonic Agents; D019210:Troponin I